1-8 of 8
Pamela Munster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L. Coveler, Steven Powell, Bruno Bastos, Elizabeth Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor Weisskittel, Hu Li, Brittany A. Borden, R. Donald Harvey, Solmaz Sahebjam, Andrés Cervantes, Austin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 522–531.
https://doi.org/10.1158/1078-0432.CCR-23-1916
Published: 01 February 2024
View article titled, Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Open the PDF for Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

James J. Harding, Melinda Telli, Pamela Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Chris Molineaux, Keith Orford, Frank Parlati, Sam H. Whiting, Mark K. Bennett, Nizar M. Tannir, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 4994–5003.
https://doi.org/10.1158/1078-0432.CCR-21-1204
Published: 15 September 2021
View article titled, A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela Munster, Rahul Aggarwal, David Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees, Emily Bergsland, Neeraj Agarwal, Joseph F. Kleha, Michael Durante, Laurel Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 1932–1939.
https://doi.org/10.1158/1078-0432.CCR-15-1665
Published: 14 April 2016
View article titled, First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Open the PDF for First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma

Cigall Kadoch, Jing Li, Valerie S. Wong, Lingjing Chen, Soonmee Cha, Pamela Munster, Clifford A. Lowell, Marc A. Shuman, James L. Rubenstein
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 1029–1041.
https://doi.org/10.1158/1078-0432.CCR-13-0474
Published: 16 February 2014
View article titled, Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Open the PDF for Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma in another window
Includes: Supplementary data
Journal Articles

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

Angela DeMichele, Donald A. Berry, JoAnne Zujewski, Sally Hunsberger, Larry Rubinstein, Joseph E. Tomaszewski, Gary Kelloff, Jane Perlmutter, Meredith Buxton, Julia Lyandres, Kathy S. Albain, Chris Benz, A. Jo Chien, Paul Haluska, Brian Leyland-Jones, Minetta C. Liu, Pamela Munster, Olufunmilayo Olopade, John W. Park, Barbara A. Parker, Lajos Pusztai, Debu Tripathy, Hope Rugo, Douglas Yee, Laura Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2817–2823.
https://doi.org/10.1158/1078-0432.CCR-12-2620
Published: 30 May 2013
View article titled, Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
Open the PDF for Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials in another window
Journal Articles

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

Pamela Munster, Douglas Marchion, Elona Bicaku, Mira Lacevic, Jongphil Kim, Barbara Centeno, Adil Daud, Anthony Neuger, Susan Minton, Daniel Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2488–2496.
https://doi.org/10.1158/1078-0432.CCR-08-1930
Published: 01 April 2009
View article titled, Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Open the PDF for Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC in another window
Journal Articles

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

George R. Simon, Christopher R. Garrett, Stephen C. Olson, Michael Langevin, Irene A. Eiseman, John J. Mahany, Charles C. Williams, Richard Lush, Adil Daud, Pamela Munster, Alberto Chiappori, Mayer Fishman, Gerold Bepler, Peter F. Lenehan, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4645–4651.
https://doi.org/10.1158/1078-0432.CCR-05-2379
Published: 09 August 2006
View article titled, Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
Open the PDF for Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study in another window
Journal Articles

Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study

Adil Daud, Nikola Valkov, Barbara Centeno, Jennifer Derderian, Patricia Sullivan, Pamela Munster, Patricia Urbas, Ronald C. DeConti, Elmer Berghorn, Zhenmei Liu, Frederick Hausheer, Daniel Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 3009–3016.
https://doi.org/10.1158/1078-0432.CCR-04-1722
Published: 18 April 2005
View article titled, Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study
Open the PDF for Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study in another window